ArticleTissue engineering and regenerative medicine2026
Geometry-Dependent Osteogenic Performance of Demineralized Dentin Matrix as a Carrier for rhBMP-2.
Article in Tissue engineering and regenerative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundDemineralized dentin matrix (DDM) is a bioactive collagen-based scaffold with intrinsic osteoinductive properties and potential as a carrier for recombinant human bone morphogenetic protein-2 (rhBMP-2). However, the influence of DDM geometry on its osteogenic performance and carrier efficiency remains unclear. This study aimed to evaluate the geometry-dependent osteogenic efficacy of DDM and its role as an rhBMP-2 delivery system.
methodsDDM was prepared in particulate (300-800 µm) and block forms (root segments with drilled pores) and compared with an absorbable collagen sponge in a subcutaneous implantation model using nude mice. Each carrier was evaluated with no rhBMP-2 or with low-dose (1 µg) or high-dose (2 µg) rhBMP-2 at 2 and 4 weeks. New bone formation was assessed using micro-computed tomography and histological/histomorphometric analyses.
resultsBoth forms of DDM demonstrated intrinsic osteoinductive capacity, inducing ectopic bone formation without exogenous rhBMP-2, whereas collagen alone showed negligible bone formation. Particulate DDM exhibited greater bone formation than block DDM, with the difference reaching statistical significance by 4 weeks. The addition of rhBMP-2 enhanced early bone formation, particularly at 2 weeks; however, by 4 weeks, DDM alone achieved comparable outcomes. Notably, particulate DDM with low-dose rhBMP-2 produced bone formation comparable to or greater than that achieved with high-dose rhBMP-2 in collagen carriers. Histological findings confirmed that DDM provided sustained osteogenesis with direct bone formation on the scaffold surface, while collagen carriers exhibited peripheral bone formation due to rapid rhBMP-2 release.
conclusionDDM is an effective osteoinductive scaffold and a superior carrier for rhBMP-2 compared to collagen. Its osteogenic performance is geometry-dependent, with particulate DDM demonstrating enhanced bone regeneration. Importantly, DDM enables effective bone formation with reduced rhBMP-2 dosage, suggesting a safer and more efficient strategy for bone regeneration.
Indexed as
Identifiers
42814313What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.